Fowey

Researchers are evaluating the effects of a triple therapy inhaler combining budesonide, glycopyrronium, and formoterol fumarate BGF MDI 32014.49.6 bcg on heart and lung outcomes in people with chronic obstructive pulmonary disease COPD who have a higher risk of heart and lung problems. This Phase III study compares this triple therapy to a dual therapy inhaler containing glycopyrronium and formoterol fumarate GFF MDI 14.49.6 bcg. The trial is randomized, double-blind, and conducted at multiple centers to assess which treatment better affects cardiopulmonary outcomes.

Researchers are evaluating the safety and effectiveness of NNC0487-0111 for treating people with excess body weight. This Phase 3 clinical trial compares the medicine with a placebo, both given as weekly injections under the skin. The study focuses on how these treatments affect weight loss and other health measures related to obesity. Participants will be randomly assigned to receive one of four dose levels of NNC0487-0111 or a matching placebo. Both treatments are given once a week using a pre-filled pen injector applied to the thigh, abdomen, or upper arm. The treatment is combined with a reduced-calorie diet and increased physical activity. The study includes an initial treatment period lasting 84 weeks, with follow-up assessments continuing to week 136 and safety monitoring through week 140. During the study, participants will undergo regular evaluations including body weight, waist circumference, blood pressure, blood sugar levels, cholesterol, and quality of life surveys. Researchers will track adverse events and treatment effects at multiple time points from the start up to week 140. Participants will be closely monitored for safety throughout the trial, which runs from the baseline visit through extended follow-up periods.

Researchers are evaluating whether the drug zilebesiran can reduce major cardiovascular events such as cardiovascular death, nonfatal heart attacks, strokes, and heart failure episodes in adults with hypertension that is not well controlled and who either have established cardiovascular disease or are at high risk for it. This phase 3, randomized, double-blind study aims to gather sufficient clinical outcome events to determine the drugs impact compared to placebo. Participants will receive either 300 mg of zilebesiran or a placebo through subcutaneous injection every six months, in addition to their usual antihypertensive medications that include at least two standard drugs, one being a diuretic. The study treatments are given as add-on therapy alongside the participants existing blood pressure management. The study will continue until enough cardiovascular events have occurred to assess the primary outcome. During the study, participants will be monitored for up to approximately five years. Researchers will track the time to the first occurrence of a combined endpoint including cardiovascular death, nonfatal myocardial infarction, nonfatal stroke, or heart failure events requiring hospitalization or urgent visits. Blood pressure changes will also be measured at six months. Safety and efficacy will be closely followed through regular visits and assessments. The long follow-up period allows for thorough evaluation of cardiovascular outcomes and treatment effects.